Opposing View: A Blind Faith in Meta-Analyses in Academia Could Be a Threat to Public Health.

for all-cause mortality, 1.3% (95% CI, 0.9%–1.7%) for myocardial infarction, and 0.4% (95% CI, 0.2%–0.6%) for stroke in people who received statins compared with placebo or usual care. The relative risk reduction (RRR) was 9% (95% CI, 5%–14%), 29% (95% CI, 22%–34%), and 14% (95% CI, 5%–22%), respectively. These findings were consistent in primary prevention and secondary prevention populations. However, significant clinical and statistical heterogeneity was observed depending on the outcomes and study populations.